Senseonics Holdings, Inc. (ARCA:SENS) to Post Q3 2017 Earnings of ($0.16) Per Share, Leerink Swann Forecasts
Senseonics Holdings, Inc. (ARCA:SENS) – Equities researchers at Leerink Swann cut their Q3 2017 earnings per share (EPS) estimates for shares of Senseonics Holdings in a report released on Wednesday. Leerink Swann analyst D. Antalffy now anticipates that the company will post earnings of ($0.16) per share for the quarter, down from their previous forecast of ($0.12). Leerink Swann also issued estimates for Senseonics Holdings’ Q4 2017 earnings at ($0.24) EPS, FY2017 earnings at ($0.66) EPS, Q1 2018 earnings at ($0.23) EPS, Q2 2018 earnings at ($0.28) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.36) EPS, FY2018 earnings at ($1.20) EPS, FY2019 earnings at ($1.33) EPS, FY2020 earnings at ($0.87) EPS and FY2021 earnings at ($0.80) EPS.
COPYRIGHT VIOLATION WARNING: “Senseonics Holdings, Inc. (ARCA:SENS) to Post Q3 2017 Earnings of ($0.16) Per Share, Leerink Swann Forecasts” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/14/senseonics-holdings-inc-arcasens-to-post-q3-2017-earnings-of-0-16-per-share-leerink-swann-forecasts.html.
Shares of Senseonics Holdings (ARCA:SENS) opened at 2.49 on Monday. The company has a 50-day moving average price of $2.17 and a 200-day moving average price of $1.98. Senseonics Holdings has a 52-week low of $1.26 and a 52-week high of $4.10. The company’s market cap is $306.77 million.
About Senseonics Holdings
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
Receive News & Ratings for Senseonics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.